Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jun;31(6):623–625. doi: 10.1111/j.1365-2125.1991.tb05583.x

Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.

M S Lennard 1
PMCID: PMC1368570  PMID: 1867956

Full text

PDF
623

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerman B., Ross S. Stereospecificity of the enzymatic biotransformation of the enantiomers of prilocaine (Citanest). Acta Pharmacol Toxicol (Copenh) 1970;28(6):445–453. doi: 10.1111/j.1600-0773.1970.tb00570.x. [DOI] [PubMed] [Google Scholar]
  2. Ariëns E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol. 1984;26(6):663–668. doi: 10.1007/BF00541922. [DOI] [PubMed] [Google Scholar]
  3. Ariëns E. J., Wuis E. W. Bias in pharmacokinetics and clinical pharmacology. Clin Pharmacol Ther. 1987 Oct;42(4):361–363. doi: 10.1038/clpt.1987.163. [DOI] [PubMed] [Google Scholar]
  4. Ariëns E. J., Wuis E. W., Veringa E. J. Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol. 1988 Jan 1;37(1):9–18. doi: 10.1016/0006-2952(88)90749-6. [DOI] [PubMed] [Google Scholar]
  5. Bannon J. A., Stewart K. A., DeLisser O., Schrogie J. J. Clinical experience with timolol maleate monotherapy of hypertension. Arch Intern Med. 1986 Apr;146(4):654–657. [PubMed] [Google Scholar]
  6. Birkett D. J. Racemates or enantiomers: regulatory approaches. Clin Exp Pharmacol Physiol. 1989 Jun;16(6):479–483. doi: 10.1111/j.1440-1681.1989.tb01591.x. [DOI] [PubMed] [Google Scholar]
  7. Campbell D. B. Stereoselectivity in clinical pharmacokinetics and drug development. Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):109–125. doi: 10.1007/BF03190194. [DOI] [PubMed] [Google Scholar]
  8. Chiou G. C. Development of D-timolol for the treatment of glaucoma and ocular hypertension. J Ocul Pharmacol. 1990 Spring;6(1):67–74. doi: 10.1089/jop.1990.6.67. [DOI] [PubMed] [Google Scholar]
  9. Clark J. A., Zimmerman H. J., Tanner L. A. Labetalol hepatotoxicity. Ann Intern Med. 1990 Aug 1;113(3):210–213. doi: 10.7326/0003-4819-113-3-210. [DOI] [PubMed] [Google Scholar]
  10. Drayer D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther. 1986 Aug;40(2):125–133. doi: 10.1038/clpt.1986.150. [DOI] [PubMed] [Google Scholar]
  11. Drayer D. E. Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man. Ther Drug Monit. 1988;10(1):1–7. [PubMed] [Google Scholar]
  12. Fraunfelder F. T., Barker A. F. Respiratory effects of timolol. N Engl J Med. 1984 Nov 29;311(22):1441–1441. doi: 10.1056/nejm198411293112213. [DOI] [PubMed] [Google Scholar]
  13. Fraunfelder F. T. Ocular beta-blockers and systemic effects. Arch Intern Med. 1986 Jun;146(6):1073–1074. [PubMed] [Google Scholar]
  14. Keates E. U., Stone R. The effect of d-timolol on intraocular pressure in patients with ocular hypertension. Am J Ophthalmol. 1984 Jul 15;98(1):73–78. doi: 10.1016/0002-9394(84)90191-0. [DOI] [PubMed] [Google Scholar]
  15. Richards R., Tattersfield A. E. Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects. Br J Clin Pharmacol. 1985 Nov;20(5):459–462. doi: 10.1111/j.1365-2125.1985.tb05097.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Simonyi M. On chiral drug action. Med Res Rev. 1984 Jul-Sep;4(3):359–413. doi: 10.1002/med.2610040304. [DOI] [PubMed] [Google Scholar]
  17. Sugiyama K., Kawai K., Kitazawa Y. [The effect of d-timolol on intraocular pressure in the normal subjects]. Nippon Ganka Gakkai Zasshi. 1986 Jun;90(6):866–870. [PubMed] [Google Scholar]
  18. Tucker G. T., Lennard M. S. Enantiomer specific pharmacokinetics. Pharmacol Ther. 1990;45(3):309–329. doi: 10.1016/0163-7258(90)90069-e. [DOI] [PubMed] [Google Scholar]
  19. Waller D. G. Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy? Br J Clin Pharmacol. 1990 Aug;30(2):157–171. doi: 10.1111/j.1365-2125.1990.tb03760.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Williams K. M. Enantiomers in arthritic disorders. Pharmacol Ther. 1990;46(2):273–295. doi: 10.1016/0163-7258(90)90095-j. [DOI] [PubMed] [Google Scholar]
  21. Williams K., Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs. 1985 Oct;30(4):333–354. doi: 10.2165/00003495-198530040-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES